What Is Corneal Cross-Linking?

Keratoconus is a degenerative corneal disease that gradually distorts the shape of the cornea over time, leading to distorted vision. During the earlier stages of this disease, prescription eyewear will often sufficiently treat the symptoms. However, as keratoconus continues to progress, a more proactive form of treatment may be needed. Traditionally, a corneal transplant has been the only option to improve the vision once keratoconus has reached advanced stages. Today, our ophthalmologists at Virginia Eye Consultants are proud to offer an innovative, non-invasive alternative.

Corneal Collagen Cross-Linking (CXL) is an FDA-approved therapy designed to slow or stop the progression of keratoconus. This procedure can help preserve vision, and in some cases, patients have even experienced vision improvement. During this 30-minute treatment, drops of riboflavin are placed into the eye and activated by light, ultimately leading to the strengthening of the cornea. CXL can delay or prevent the need for a corneal transplant, helping patients to avoid the need for invasive surgery.

To learn more information about Corneal Collagen Cross-Linking (CXL) and your keratoconus treatment options, or to schedule a consultation with one of our doctors, please contact Virginia Eye Consultants today.